These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 18477712)

  • 1. The Peripheral Profile of the Chitinase 3-like-1 in Benign Multiple Sclerosis - A Single Centre's Experience.
    Barcutean L; Hutanu A; Andone S; Maier S; Balasa R
    CNS Neurol Disord Drug Targets; 2024; 23(6):791-799. PubMed ID: 37303176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impairment and restrictions in possibly benign multiple sclerosis.
    Schaefer LM; Poettgen J; Fischer A; Gold S; Stellmann JP; Heesen C
    Brain Behav; 2019 Apr; 9(4):e01259. PubMed ID: 30884218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How common is truly benign MS in a UK population?
    Tallantyre EC; Major PC; Atherton MJ; Davies WA; Joseph F; Tomassini V; Pickersgill TP; Harding KE; Willis MD; Winter M; Robertson NP
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):522-528. PubMed ID: 30177509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
    Sartori A; Abdoli M; Freedman MS
    J Neurol; 2017 Jun; 264(6):1068-1075. PubMed ID: 28417192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating typical multiple sclerosis disability progression speed from clinical observations.
    Brown MG; Asbridge M; Hicks V; Kirby S; Murray TJ; Andreou P; Lin D
    PLoS One; 2014; 9(10):e105123. PubMed ID: 25329469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis.
    Dimisianos N; Rodi M; Kalavrizioti D; Georgiou V; Papathanasopoulos P; Mouzaki A
    Mult Scler Int; 2014; 2014():436764. PubMed ID: 25152817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.
    Gajofatto A; Calabrese M; Benedetti MD; Monaco S
    Dis Markers; 2013; 35(6):687-99. PubMed ID: 24324285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration.
    Achtnichts L; Gonen O; Rigotti DJ; Babb JS; Naegelin Y; Penner IK; Bendfeldt K; Hirsch J; Amann M; Kappos L; Gass A
    Eur J Radiol; 2013 Dec; 82(12):e848-52. PubMed ID: 24041438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disability in multiple sclerosis: a reference for patients and clinicians.
    Kister I; Chamot E; Salter AR; Cutter GR; Bacon TE; Herbert J
    Neurology; 2013 Mar; 80(11):1018-24. PubMed ID: 23427319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benign multiple sclerosis: does it exist?
    Correale J; Ysrraelit MC; Fiol MP
    Curr Neurol Neurosci Rep; 2012 Oct; 12(5):601-9. PubMed ID: 22777531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis.
    Rigotti DJ; Inglese M; Kirov II; Gorynski E; Perry NN; Babb JS; Herbert J; Grossman RI; Gonen O
    Neurology; 2012 May; 78(18):1383-9. PubMed ID: 22517095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.
    Galetta KM; Graves J; Talman LS; Lile DJ; Frohman EM; Calabresi PA; Galetta SL; Balcer LJ
    J Neuroophthalmol; 2012 Jun; 32(2):116-23. PubMed ID: 22269944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative T2' imaging in patients with clinically isolated syndrome.
    Reitz LY; Inglese M; Fiehler J; Finsterbusch J; Holst B; Heesen C; Martin R; Schippling S
    Acta Neurol Scand; 2012 Nov; 126(5):357-63. PubMed ID: 22211987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.
    Rigotti DJ; Gass A; Achtnichts L; Inglese M; Babb JS; Naegelin Y; Hirsch J; Amann M; Kappos L; Gonen O
    Mult Scler; 2012 Jan; 18(1):98-107. PubMed ID: 21921070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global N-acetylaspartate declines even in benign multiple sclerosis.
    Rigotti DJ; Gonen O; Grossman RI; Babb JS; Falini A; Benedetti B; Filippi M
    AJNR Am J Neuroradiol; 2011 Jan; 32(1):204-9. PubMed ID: 20966065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical relevance of criteria for designating multiple sclerosis as benign after 10 years of disease.
    Costelloe L; Thompson A; Walsh C; Tubridy N; Hutchinson M
    J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1245-8. PubMed ID: 18477712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors.
    Hawkins SA; McDonnell GV
    J Neurol Neurosurg Psychiatry; 1999 Aug; 67(2):148-52. PubMed ID: 10406979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rate of brain atrophy in benign vs early multiple sclerosis.
    Gauthier SA; Berger AM; Liptak Z; Duan Y; Egorova S; Buckle GJ; Glanz BI; Khoury SJ; Bakshi R; Weiner HL; Guttmann CR
    Arch Neurol; 2009 Feb; 66(2):234-7. PubMed ID: 19204160
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.